GoodRx Holdings, Inc.

NasdaqGS:GDRX Stock Report

Market Cap: US$1.7b

GoodRx Holdings Future Growth

Future criteria checks 4/6

GoodRx Holdings is forecast to grow earnings and revenue by 48% and 5.9% per annum respectively. EPS is expected to grow by 49% per annum. Return on equity is forecast to be 21.8% in 3 years.

Key information

48.0%

Earnings growth rate

49.0%

EPS growth rate

Healthcare Services earnings growth31.8%
Revenue growth rate5.9%
Future return on equity21.8%
Analyst coverage

Good

Last updated20 Dec 2024

Recent future growth updates

Recent updates

Capital Allocation Trends At GoodRx Holdings (NASDAQ:GDRX) Aren't Ideal

Dec 21
Capital Allocation Trends At GoodRx Holdings (NASDAQ:GDRX) Aren't Ideal

GoodRx Holdings, Inc.'s (NASDAQ:GDRX) Shares May Have Run Too Fast Too Soon

Oct 29
GoodRx Holdings, Inc.'s (NASDAQ:GDRX) Shares May Have Run Too Fast Too Soon

GoodRx: The Tide Is Turning The Wrong Way (Rating Downgrade)

Oct 26

GoodRx Holdings: Failing To Gain Much Traction

Oct 08

GoodRx Holdings' (NASDAQ:GDRX) Returns On Capital Not Reflecting Well On The Business

Sep 22
GoodRx Holdings' (NASDAQ:GDRX) Returns On Capital Not Reflecting Well On The Business

GoodRx Q2 Earnings Preview

Jul 31

GoodRx Holdings (NASDAQ:GDRX) Could Easily Take On More Debt

Jul 12
GoodRx Holdings (NASDAQ:GDRX) Could Easily Take On More Debt

GoodRx Holdings, Inc.'s (NASDAQ:GDRX) 30% Price Boost Is Out Of Tune With Revenues

Jun 09
GoodRx Holdings, Inc.'s (NASDAQ:GDRX) 30% Price Boost Is Out Of Tune With Revenues

Returns On Capital At GoodRx Holdings (NASDAQ:GDRX) Paint A Concerning Picture

Jun 06
Returns On Capital At GoodRx Holdings (NASDAQ:GDRX) Paint A Concerning Picture

GoodRx: Encouraging Profit Stabilization (Rating Upgrade)

May 28

GoodRx Holdings: Large TAM Continues To Support Growth

Mar 20

GoodRx Holdings, Inc. (NASDAQ:GDRX) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Mar 07
GoodRx Holdings, Inc. (NASDAQ:GDRX) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Is GoodRx Holdings, Inc. (NASDAQ:GDRX) Trading At A 24% Discount?

Mar 01
Is GoodRx Holdings, Inc. (NASDAQ:GDRX) Trading At A 24% Discount?

GoodRx Holdings (NASDAQ:GDRX) Has A Rock Solid Balance Sheet

Feb 12
GoodRx Holdings (NASDAQ:GDRX) Has A Rock Solid Balance Sheet

GoodRx: Cost Saving Is A Strong Value Proposition To Consumers

Jan 23

GoodRx Holdings (NASDAQ:GDRX) May Have Issues Allocating Its Capital

Jan 22
GoodRx Holdings (NASDAQ:GDRX) May Have Issues Allocating Its Capital

GoodRx Stock Spikes After Receiving A Strong Dose Of Performance

Jan 11

What Is GoodRx Holdings, Inc.'s (NASDAQ:GDRX) Share Price Doing?

Dec 02
What Is GoodRx Holdings, Inc.'s (NASDAQ:GDRX) Share Price Doing?

GoodRx Holdings (NASDAQ:GDRX) May Have Issues Allocating Its Capital

Sep 12
GoodRx Holdings (NASDAQ:GDRX) May Have Issues Allocating Its Capital

An Intrinsic Calculation For GoodRx Holdings, Inc. (NASDAQ:GDRX) Suggests It's 41% Undervalued

Jul 14
An Intrinsic Calculation For GoodRx Holdings, Inc. (NASDAQ:GDRX) Suggests It's 41% Undervalued

GoodRx Holdings' (NASDAQ:GDRX) Returns On Capital Not Reflecting Well On The Business

May 27
GoodRx Holdings' (NASDAQ:GDRX) Returns On Capital Not Reflecting Well On The Business

Some Confidence Is Lacking In GoodRx Holdings, Inc. (NASDAQ:GDRX) As Shares Slide 27%

May 05
Some Confidence Is Lacking In GoodRx Holdings, Inc. (NASDAQ:GDRX) As Shares Slide 27%

Investors Give GoodRx Holdings, Inc. (NASDAQ:GDRX) Shares A 27% Hiding

May 05
Investors Give GoodRx Holdings, Inc. (NASDAQ:GDRX) Shares A 27% Hiding

Is There An Opportunity With GoodRx Holdings, Inc.'s (NASDAQ:GDRX) 45% Undervaluation?

Mar 23
Is There An Opportunity With GoodRx Holdings, Inc.'s (NASDAQ:GDRX) 45% Undervaluation?

GoodRx Holdings (NASDAQ:GDRX) May Have Issues Allocating Its Capital

Feb 07
GoodRx Holdings (NASDAQ:GDRX) May Have Issues Allocating Its Capital

Earnings and Revenue Growth Forecasts

NasdaqGS:GDRX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20268849719424114
12/31/20258267017122017
12/31/20247943115520817
9/30/2024790-1688155N/A
6/30/2024775-5964128N/A
3/31/2024764-786149N/A
12/31/2023750-983138N/A
9/30/20237381596154N/A
6/30/20237451269128N/A
3/31/2023747-4892149N/A
12/31/2022767-3392147N/A
9/30/2022796-71116165N/A
6/30/2022803-47136180N/A
3/31/2022788-15126163N/A
12/31/2021745-25144179N/A
9/30/2021686-282109144N/A
6/30/2021631-31484128N/A
3/31/2021578-31089131N/A
12/31/2020551-29496131N/A
9/30/202051013105133N/A
6/30/202047275105117N/A
3/31/20204355096104N/A
12/31/2019388427883N/A
12/31/2018250144245N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GDRX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: GDRX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: GDRX is expected to become profitable in the next 3 years.

Revenue vs Market: GDRX's revenue (5.9% per year) is forecast to grow slower than the US market (9.1% per year).

High Growth Revenue: GDRX's revenue (5.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: GDRX's Return on Equity is forecast to be high in 3 years time (21.8%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 02:23
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

GoodRx Holdings, Inc. is covered by 28 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Vikram KesavabhotlaBaird
Ishan MajumdarBaptista Research
Michael ChernyBofA Global Research